Učitavanje...
Pharmacology of tyrosine kinase inhibitors in chronic myeloid leukemia; a clinician’s perspective
OBJECTIVE: In this review, we have summarized the pharmacokinetics, pharmacodynamics and adverse effects of imatinib, dasatinib, nilotinib, bosutinib, ponatinib and radotinib with focus on pharmacogenomic studies with clinical end points. We have discussed the key phase 3 trials of tyrosine kinase i...
Spremljeno u:
| Izdano u: | Daru |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Springer International Publishing
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7214547/ https://ncbi.nlm.nih.gov/pubmed/31900888 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40199-019-00321-z |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|